Search - tctmd.com

Displaying 921 - 940 of 2241

Sort: Relevancy | Date

Presentation

Influence of Second- and Third-Degree Heart Block on 30-Day Outcomes After AMI in the DES Era

Presenter: H.L. Kim

October 09, 2014

News Daily News

对于所有适应症，DES与低于BMS的院内死亡率有联系

Todd Neale

October 03, 2014

News Daily News

Los SLF se asocian a una Menor Mortalidad Intrahospitalaria que los SMD para Todas las Indicaciones de las PCI

Todd Neale

October 03, 2014

News Daily News

DES Linked With Lower In-Hospital Mortality Than BMS for All PCI Indications

Todd Neale

October 03, 2014

Presentation

Impact on In-Hospital Outcomes with DES vs BMS

Presenter: Apurva O. Badheka

October 01, 2014

News Conference News TCT 2014

Long-term Outcomes Worse for Patients with Coronary Artery Aneurysm After DES Implantation

Yael L. Maxwell

September 19, 2014

News Conference News TCT 2014

Bioabsorbable Polymer DES Represent Evolution to Stenting Platform

September 19, 2014

Presentation TCT 2014

Thoughtful Insights

Presenter: Pascal Vranckx

September 17, 2014

Presentation TCT 2014

Case Presentation

Presenter: Matthew J. Price

September 17, 2014

Presentation TCT 2014

Con: The Psychological Attraction Will Pass When the Data Emerges!

Presenter: Daniel I. Simon

September 16, 2014

Presentation TCT 2014

Pro: Within 10 Years, Most Coronary Intervention Will Use BRS!

Presenter: Stephan Achenbach

September 16, 2014

Presentation TCT 2014

TCT 612: Clinical Outcomes in Patients with Calcified Lesions Treated with Bioresorbable Vascular Scaffolds

Presenter: Dariusz Dudek, Pieter C. Smits, Vincent On-Hing Kwok, Vasileios Panoulas

September 16, 2014

Presentation TCT 2014

Status of DCB for PVD and Lessons Learned from the Recent FDA Panel

Presenter: Andrew Farb, Mitchell W. Krucoff, Aaron V. Kaplan, Juan F. Granada

September 16, 2014

Presentation TCT 2014

TCT 611: Multimodality Assessment 12 Months After Implantation of a Bioresorbable Scaffold for the Treatment of Culprit Lesions in Myocardial Infarction

Presenter: Dariusz Dudek, Pieter C. Smits, Vincent On-Hing Kwok, Ulrich Hink

September 16, 2014

Presentation TCT 2014

The Emphatic Case for OPCs NOW for New DES Approval in the United States!

Presenter: Andrew Farb, Mitchell W. Krucoff, Aaron V. Kaplan, Laura Mauri

September 16, 2014

Presentation TCT 2014

Imaging to Guide BRS: Nice to Have or Must Have?

Presenter: Dariusz Dudek, Pieter C. Smits, Vincent On-Hing Kwok, Evelyn S. Regar

September 16, 2014

Presentation TCT 2014

Device Approval Considerations (Preclinical and Clinical) for Bioresorbable Scaffolds: Update on FDA Regulatory Guidelines

Presenter: Andrew Farb, Mitchell W. Krucoff, Aaron V. Kaplan, Kenya Brothers

September 16, 2014

Presentation TCT 2014

Tips, Tricks, and Pearls to Optimize BRS Outcomes: From Lesion Preparation to Pharmacotherapy Considerations

Presenter: Dariusz Dudek, Pieter C. Smits, Vincent On-Hing Kwok, Jonathan M. Hill

September 16, 2014

Presentation TCT 2014

What Kind of Lesions are BRS Preferred in TODAY? TOMORROW?

Presenter: Dariusz Dudek, Pieter C. Smits, Vincent On-Hing Kwok, Azeem Latib

September 16, 2014

Presentation TCT 2014

BRS Under Development V Biolute BRS

Presenter: Alexandre Abizaid, Dean J. Kereiakes, Vasim Farooq, Dinesh Shah

September 16, 2014

Advertisement

Influence of Second- and Third-Degree Heart Block on 30-Day Outcomes After AMI in the DES Era

对于所有适应症，DES与低于BMS的院内死亡率有联系

Los SLF se asocian a una Menor Mortalidad Intrahospitalaria que los SMD para Todas las Indicaciones de las PCI

DES Linked With Lower In-Hospital Mortality Than BMS for All PCI Indications

Impact on In-Hospital Outcomes with DES vs BMS

Long-term Outcomes Worse for Patients with Coronary Artery Aneurysm After DES Implantation

Bioabsorbable Polymer DES Represent Evolution to Stenting Platform

Thoughtful Insights

Case Presentation

Con: The Psychological Attraction Will Pass When the Data Emerges!

Pro: Within 10 Years, Most Coronary Intervention Will Use BRS!

TCT 612: Clinical Outcomes in Patients with Calcified Lesions Treated with Bioresorbable Vascular Scaffolds

Status of DCB for PVD and Lessons Learned from the Recent FDA Panel

TCT 611: Multimodality Assessment 12 Months After Implantation of a Bioresorbable Scaffold for the Treatment of Culprit Lesions in Myocardial Infarction

The Emphatic Case for OPCs NOW for New DES Approval in the United States!

Imaging to Guide BRS: Nice to Have or Must Have?

Device Approval Considerations (Preclinical and Clinical) for Bioresorbable Scaffolds: Update on FDA Regulatory Guidelines

Tips, Tricks, and Pearls to Optimize BRS Outcomes: From Lesion Preparation to Pharmacotherapy Considerations

What Kind of Lesions are BRS Preferred in TODAY? TOMORROW?

BRS Under Development V Biolute BRS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content